Navigation Links
BioMarin to Present at the Goldman Sachs Healthcare Conference
Date:6/2/2009

NOVATO, Calif., June 2 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Goldman Sachs 30th Annual Global Healthcare Conference in New York City on Tuesday, June 9, 2009 at 9:00 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                          Media
    Eugenia Shen                       Susan Berg
    BioMarin Pharmaceutical Inc.       BioMarin Pharmaceutical Inc.
    (415) 506-6570                     (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
9. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
10. BioMarin to Present at the Morgan Stanley Healthcare Conference
11. BioMarin Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
(Date:11/30/2016)... , November 30, 2016 Part of ... ... Aptuit, LLC today announced that it had ... additional 150,000 novel compounds have increased the Screening Collection to ... the hit discovery capabilities of the company. This expansion, complemented ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader ... the implications of the latest FDA guidance on pharmaceutical cocrystals as drug substance ... Cambridge, MA. , The event follows the successful November 15th event that ...
(Date:11/30/2016)... Park, NC (PRWEB) , ... November 30, 2016 ... ... company engaged in the development of a new orally administered treatment for Alzheimer’s ... and neuroimaging results of a Phase 2a clinical trial of T3D-959 in mild ...
Breaking Biology Technology:
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/29/2016)... BioDirection, a privately held medical device company ... detection of concussion and other traumatic brain injury (TBI), ... meeting with the U.S. Food and Drug Administration (FDA) ... During the meeting company representatives reviewed plans for clinical ... commencement of a planned pilot trial. ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
Breaking Biology News(10 mins):